Tags: Drug.
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis also known as scleroderma. Touted as a drug of the future metelimumab was dropped from further development in favour of fresolimumab which is currently being developed by Genzyme.